VAL001 – Business Opportunity Summary. A. Mansson, Non-Executive Director, Respiratorius AB. Respiratorius AB develops new and effective candidate drugs for treatment of cancer, COPD and asthma. VAL001 is an orphan drug designated asset that is phase III ready. The indication is Diffuse Large B-Cell Lymphoma (DLBCL).